Caitong International Asset Management’s Atossa Therapeutics ATOS Stock Holding History

Caitong International Asset Management’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12	Buy	+6	New	+$27	﹤0.01%	2606

Other funds holding ATOS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caitong International Asset Management's ATOS Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Atossa Therapeutics (ATOS) in Q2 2026: 6 shares worth $12. The stake represents ﹤0.01% of the portfolio and ranks #2606 among its holdings.

31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

Caitong International Asset Management held 6 shares of Atossa Therapeutics worth $12 as of Q2 2026.
Atossa Therapeutics was a new Caitong International Asset Management position in Q2 2026.
Atossa Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2606 holding.
31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.